About sumitomo dainippon pharma - DNPUF
Sumitomo Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.
DNPUF At a Glance
Sumitomo Pharma Co., Ltd.
2-6-8 Dosho-machi
Osaka, Osaka 541-0045
| Phone | 81-6-6203-5321 | Revenue | 2.62B | |
| Industry | Pharmaceuticals: Major | Net Income | 155.03M | |
| Sector | Health Technology | 2025 Sales Growth | 20.107% | |
| Fiscal Year-end | 03 / 2026 | Employees | 3,832 | |
| View SEC Filings |
DNPUF Valuation
| P/E Current | 7.472 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 12.493 |
| Price to Sales Ratio | 0.74 |
| Price to Book Ratio | 1.709 |
| Price to Cash Flow Ratio | 17.89 |
| Enterprise Value to EBITDA | 12.339 |
| Enterprise Value to Sales | 1.484 |
| Total Debt to Enterprise Value | 0.541 |
DNPUF Efficiency
| Revenue/Employee | 682,709.62 |
| Income Per Employee | 40,456.029 |
| Receivables Turnover | 5.033 |
| Total Asset Turnover | 0.477 |
DNPUF Liquidity
| Current Ratio | 1.052 |
| Quick Ratio | 0.661 |
| Cash Ratio | 0.096 |
DNPUF Profitability
| Gross Margin | 56.509 |
| Operating Margin | 5.622 |
| Pretax Margin | 4.416 |
| Net Margin | 5.926 |
| Return on Assets | 2.828 |
| Return on Equity | 14.324 |
| Return on Total Capital | 4.793 |
| Return on Invested Capital | 6.395 |
DNPUF Capital Structure
| Total Debt to Total Equity | 185.419 |
| Total Debt to Total Capital | 64.964 |
| Total Debt to Total Assets | 42.317 |
| Long-Term Debt to Equity | 156.038 |
| Long-Term Debt to Total Capital | 54.67 |